Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Glucagon-Like Peptide-1 Human ELISA (Multispecies specificity)

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Other names:GLP-1
  • Species:Human, Mouse, Rat
Please select your region to see available products and prices.
Cat. No. Size Price

RSCYK160R 96 wells (1 kit)
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antibody




At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.206-50 ng/mL

Intra-assay (Within-Run)

Rat plasma - CV 5.36 - 6.60 Human plasma - CV 4.69 - 10.67

Inter-assay (Run-to-Run)

Rat plasma - CV 5.51 -18.87 Human plasma - CV 9.63 - 17.57

Spiking Recovery

Rat plasma - 102,6% Human plasma - 97,7%


Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Animal studies


GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. The mammalian proglucagon 1) is synthesized in the neuroendocrine L-cell of the intestine and the alpha-cells of the pancreas. It contains within its structure the sequences of glucagon and two glucagon-like peptides (GLP-1 and GLP-2) in tandem flanked at their amino and carboxyl termini by dibasic residues. GLP-1 is a 37 amino acids peptide and produced in the small intestine and in the pancreas in the human, in either C-terminal-amidated on glycine-extended form2) 3). GLP1 (7-36) amide and its receptor are present in several brain regions and may play a role in the physiological control of feeding4). Several reports have been presented as follows as to the biological activities of GLP-1. GLP-1 (7-37) and (7-36) amide is known as one of the most potent insulin secretagogues 5). GLP-1 (7-36) amide was supposed to improved glycemic control in patients with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism6). Intravenous GLP-1 (7-37) and (7-36) amide could normalize fasting hyperglycaemia in type 2 diabetic patients7). Hyperglycaemia during parenteral nutrition could be controlled by exogenous GLP-1, whereas the chronic therapy of type 2 diabetes required GLP-1 derivatives with longer duration of action 8). Recombinant GLP-1 (7-36) amide was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion, 5-day treatment of hereby obese human subjects with GLP-1 at high doses by prandial subcutaneous infusion promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and reduced food intake with an ensuing weight loss9). A G-protein-coupled receptor, GPR120, which is abundantly expressed in intestine, functions as a receptor for unsaturated long-chain FFAs (free fatty acids). The stimulation of GPR120 by FFAs promotes the secretion of GLP-1 in vitro (measured by YK160, Yanaihara Institute Inc) and in vivo, and increases circulation insulin, indicate that GPR120-mediated GLP-1 secretion induced by dietary FFAs is important in the treatment of diabetes10). All these approaches have shown remarkable efficacy in both experimental and clinical studies. The GLP-1-based therapy of type 2 diabetes, therefore, represents a new and attractive alternative11). Yanaihara Institute Inc. developed a quantitative EIA kit with high specificity and sensitivity (detection limit 0.206ng/mL) for rat/mouse/human GLP-1 (YK160) as a useful tool for these necessaries.

Product References (6)


  • Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKCpathways. Metabolism. 2013 Sep;62(9):1279-86. doi: 10.1016/j.metabol.2013.04.010.Epub 2013 May 14. PubMed PMID: 23684008; PubMed Central PMCID: PMC3755020. See more on PubMed
  • Rauchenzauner M, Laimer M, Wiedmann M, Tschoner A, Salzmann K, Sturm W,Sandhofer A, Walser G, Luef G, Ebenbichler CF. The novel insulin resistanceparameters RBP4 and GLP-1 in patients treated with valproic acid: just asidestep? Epilepsy Res. 2013 May;104(3):285-8. doi:10.1016/j.eplepsyres.2012.10.004. Epub 2012 Nov 20. PubMed PMID: 23182413. See more on PubMed
  • Choi SH, Leem J, Lee IK. Protective Effects of Gemigliptin, a DipeptidylPeptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.Mediators Inflamm. 2017;2017:4139439. doi: 10.1155/2017/4139439. Epub 2017 Nov28. PubMed PMID: 29317794; PubMed Central PMCID: PMC5727799. See more on PubMed
  • Salis ER, Reith DM, Wheeler BJ, Broadbent RS, Medlicott NJ. Insulinresistance, glucagon-like peptide-1 and factors influencing glucose homeostasisin neonates. Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F162-F166. doi:10.1136/archdischild-2015-309174. Epub 2016 Sep 2. PubMed PMID: 27589992. See more on PubMed
  • Zahradka P, Wright B, Weighell W, Blewett H, Baldwin A, O K, Guzman RP, TaylorCG. Daily non-soy legume consumption reverses vascular impairment due toperipheral artery disease. Atherosclerosis. 2013 Oct;230(2):310-4. doi:10.1016/j.atherosclerosis.2013.07.048. Epub 2013 Aug 6. PubMed PMID: 24075762. See more on PubMed
  • Vihonen H, Kuisma M, Salo A, Ångerman S, Pietiläinen K, Nurmi J. Mechanisms ofearly glucose regulation disturbance after out-of-hospital cardiopulmonaryresuscitation: An explorative prospective study. PLoS One. 2019 Mar25;14(3):e0214209. doi: 10.1371/journal.pone.0214209. eCollection 2019. PubMedPMID: 30908518; PubMed Central PMCID: PMC6433228. See more on PubMed
Summary References (11)

References to Glucagon-Like Peptide-1

  • Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
  • Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
  • Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
  • Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
  • Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
  • Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
  • Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
  • Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
  • Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
  • Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
  • Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8
Related Products Docs